Haemonetics (HAE) AI Stock Analysis

• Market Cap: $2.41B
• Dividend Yield: N/A
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): 15.6
• Beta (1Y): 0.73
• Revenue Growth: 0.91%
• EPS Growth: 45.81%
• Country: US
• Employees: 3,657
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.10
• Shares Outstanding: 48,177,258
• 10 Day Avg. Volume: 1,115,203
• 30 Day Avg. Volume: 1,267,148
• PEG Ratio: 0.44
• Price to Book (P/B): 3.87
• Price to Sales (P/S): 2.34
• P/FCF Ratio: 22.33
• Enterprise Value/Market Cap: 1.87
• Enterprise Value/Revenue: 3.34
• Enterprise Value/Gross Profit: 5.96
• Enterprise Value/Ebitda: 12.99
• 1Y Price Target: $73.00
• Price Target Upside: 42.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 68 Neutral
• Price Target: $58.00 ▲(13.39% Upside)

Haemonetics' overall stock score is driven by strong financial performance and positive earnings call insights, indicating robust growth in key areas and effective margin management. However, technical analysis reveals bearish trends, and valuation metrics suggest moderate attractiveness. Addressing revenue growth challenges and leveraging strategic initiatives will be crucial for future performance.

Positive Factors

Organic Revenue Growth

Strong organic growth indicates robust demand for core products, enhancing long-term revenue potential and market position.

Margin Expansion

Improved margins reflect operational efficiency and pricing power, supporting sustainable profitability and competitive advantage.

Plasma Segment Performance

Strong growth in the plasma segment underscores the effectiveness of technology upgrades, boosting long-term revenue streams.

Negative Factors

Revenue Decline

Revenue decline due to portfolio transitions may signal challenges in adapting to market changes, impacting short-term financial performance.

High Leverage

High leverage can strain financial flexibility and increase risk, potentially affecting long-term stability and investment capacity.

Interventional Technologies Challenges

Decline in interventional technologies highlights competitive and operational challenges, potentially limiting growth in this segment.

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation (HAE) is a global healthcare company that specializes in blood management solutions. Founded in 1971 and headquartered in Braintree, Massachusetts, Haemonetics operates in various sectors including blood component collection, transfusion medicine, and surgical blood management. Its core products and services include automated blood collection systems, blood processing equipment, and software solutions designed to enhance the efficiency and safety of blood management practices in hospitals and blood centers worldwide.

How the Company Makes Money

Haemonetics generates revenue primarily through the sale of its medical devices and equipment, which includes automated blood collection systems such as the TEG (Thromboelastography) system and blood component separation technologies. The company also earns income from service contracts, maintenance, and software solutions that accompany its devices, ensuring ongoing support and updates for healthcare providers. Key revenue streams include the sale of consumables used in blood collection processes, which are recurring in nature. Strategic partnerships with blood banks, hospitals, and healthcare systems enhance its market presence and contribute to its earnings by providing integrated solutions that improve patient care and operational efficiency.

Haemonetics Financial Statement Overview

Summary

Haemonetics demonstrates strong profitability and cash flow management, with robust margins and effective cash conversion. However, challenges include declining revenue growth and high leverage, which need to be addressed for sustained financial health.

Income Statement

Haemonetics shows strong profitability with a consistent gross profit margin around 56% in TTM, and a stable net profit margin of 12.1%. However, the revenue growth rate has declined by 1.1% in TTM, indicating a potential slowdown in sales growth. EBIT and EBITDA margins remain healthy, reflecting efficient operations.

Balance Sheet

The company has a high debt-to-equity ratio of 1.39 in TTM, suggesting significant leverage, which could pose risks if not managed carefully. However, the return on equity is robust at 18.7%, indicating effective use of equity to generate profits. The equity ratio is moderate, reflecting a balanced asset structure.

Cash Flow

Haemonetics demonstrates strong cash flow management with a 32.8% growth in free cash flow in TTM. The operating cash flow to net income ratio is 0.43, and the free cash flow to net income ratio is 0.84, indicating good cash conversion efficiency. This positions the company well for future investments and debt servicing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.35B	1.36B	1.31B	1.17B	993.20M	870.46M
Gross Profit	754.50M	748.96M	691.55M	615.10M	505.50M	397.84M
EBITDA	346.51M	337.40M	265.58M	249.34M	178.50M	142.25M
Net Income	163.34M	167.68M	117.56M	115.40M	43.38M	79.47M
Balance Sheet
Total Assets	2.46B	2.45B	2.20B	1.93B	1.86B	1.82B
Cash, Cash Equivalents and Short-Term Investments	292.90M	306.76M	178.80M	284.47M	259.50M	192.31M
Total Debt	1.22B	1.22B	807.79M	765.89M	773.59M	707.61M
Total Liabilities	1.58B	1.63B	1.24B	1.12B	1.11B	1.09B
Stockholders Equity	882.30M	820.84M	959.96M	818.00M	749.42M	731.67M
Cash Flow
Free Cash Flow	189.16M	142.45M	115.45M	162.87M	75.75M	71.77M
Operating Cash Flow	226.54M	181.72M	181.75M	273.06M	172.26M	108.81M
Investing Cash Flow	-55.70M	-161.90M	-322.39M	-143.79M	-86.34M	-425.44M
Financing Cash Flow	-227.32M	108.82M	38.16M	-100.36M	-15.75M	367.45M

Haemonetics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 51.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Negative. The current price of 51.15 is below the 20-day moving average (MA) of 53.39, below the 50-day MA of 61.60, and below the 200-day MA of 67.48, indicating a bearish trend. The MACD of -2.65 indicates Negative momentum. The RSI at 30.55 is Neutral, neither overbought nor oversold. The STOCH value of 22.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAE.

Haemonetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TFX	73 Outperform	5.55B	29.57	1.63%	1.08%	1.11%	-23.73%
ATR	72 Outperform	8.87B	23.23	14.50%	1.34%	1.51%	21.70%
BDX	70 Outperform	53.76B	33.73	6.30%	2.21%	7.86%	14.24%
HOLX	69 Neutral	15.17B	28.33	11.50%	―	1.28%	-17.73%
HAE	68 Neutral	$2.41B	15.61	18.27%	―	0.91%	45.81%
ICUI	53 Neutral	3.19B	-87.34	-1.75%	―	2.95%	47.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Haemonetics Corporate Events

Haemonetics Holds Successful Annual Shareholders Meeting

On July 24, 2025, Haemonetics Corporation held its Annual Meeting of Shareholders, achieving a quorum with 94.95% of shares represented. During the meeting, shareholders elected nine directors for one-year terms, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending March 28, 2026.